Remove Obesity Remove Preserved Ejection Fraction Remove Quality of Life
article thumbnail

SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity

American College of Cardiology

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.

article thumbnail

The Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction "Twindemic” - Shared Root Causes and Treatment Targets

HeartRhythm

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′.

article thumbnail

Letter by Weir Regarding Article, “Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity”

Circulation

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

article thumbnail

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9)

article thumbnail

Abstract 4118122: Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction

Circulation

The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients studied were older (68 years old), white (90%), obese (average BMI 34 kg/m2) individuals with an average LVEF of 61%. Patients were divided into two groups based on BB use at trial enrollment.

article thumbnail

Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity

Circulation

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions: